Disease · MONDO_0002203

constipation disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. constipation disorder. Diseases, record MONDO_0002203. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002203

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: constipation disorder; Open Targets
Open Targets ID: MONDO_0002203; Open Targets
Other names: Costiveness, Dyschezia, constipation; Open Targets
Disease Ontology: DOID:2089; Disease Ontology
MeSH: D003248; MeSH
NCI Thesaurus: C37930; NCI Thesaurus
Highest stage of its drugs: Approval, for 55 of its 99 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs99

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
POLYETHYLENE GLYCOL 3350	CHEMBL1201479	Small molecule	Approval	DailyMed	40	21	19	Drugs and targets
PRUCALOPRIDE	CHEMBL117287	Small molecule	Approval	ATC, EMA Human Drugs and TTD	20	17	17	Drugs and targets
LUBIPROSTONE	CHEMBL1201134	Small molecule	Approval	ATC, DailyMed and PMDA	23	15	15	Drugs and targets
LINACLOTIDE	CHEMBL3301675	Protein	Approval	ATC, DailyMed, PMDA and TTD	16	12	12	Drugs and targets
LACTULOSE	CHEMBL296306	Small molecule	Approval	ATC, DailyMed, PMDA and TTD	34	11	11	Drugs and targets
POLYETHYLENE GLYCOL	CHEMBL1201478	Small molecule	Approval	ATC and TTD	14	11	11	Drugs and targets
NALOXEGOL	CHEMBL2219418	Small molecule	Approval	ATC and EMA Human Drugs	11	9	9	Drugs and targets
TEGASEROD	CHEMBL76370	Small molecule	Approval	ATC and TTD	11	9	9	Drugs and targets
PLECANATIDE	CHEMBL2103867	Protein	Approval	ATC and FDA	9	7	7	Drugs and targets
SENNA	CHEMBL2108558		Approval	ATC and DailyMed	9	6	6	Drugs and targets

1 to 10 of 99

See all 99 drugs

Targets47

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
OPRM1	Mu-type opioid receptor	15	Mu opioid receptor agonist; Mu opioid receptor antagonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4988	Drugs and targets
HTR4	5-hydroxytryptamine receptor 4	8	Serotonin 4 (5-HT4) receptor agonist; Serotonin 4 (5-HT4) receptor partial agonist	Approval	https://conductscience.org/library/genes/3360	Drugs and targets
GUCY2C	Guanylyl cyclase C	3	Heat-stable enterotoxin receptor agonist	Approval	https://conductscience.org/library/genes/2984	Drugs and targets
ACHE	Acetylcholinesterase	2	Acetylcholinesterase inhibitor	Phase 2	https://conductscience.org/library/genes/43	Drugs and targets
HTR3A	5-hydroxytryptamine receptor 3A	2	Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist	Phase 1	https://conductscience.org/library/genes/3359	Drugs and targets
OPRD1	Opioid receptors; mu/kappa/delta	2	Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4985	Drugs and targets
OPRK1	Opioid receptors; mu/kappa/delta	2	Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4986	Drugs and targets
SLC10A2	Ileal sodium/bile acid cotransporter	2	Ileal bile acid transporter inhibitor	Approval	https://conductscience.org/library/genes/6555	Drugs and targets
SLC9A3	Sodium/hydrogen exchanger 3	2	Sodium/hydrogen exchanger 3 inhibitor	Approval	https://conductscience.org/library/genes/6550	Drugs and targets
ADRA1A	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 agonist	Phase 2	https://conductscience.org/library/genes/148	Drugs and targets

1 to 10 of 47

See all 47 targets

Trials185

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01919697	Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)	Phase 3	2,370	2019-07-02	Chronic Idiopathic Constipation	PLECANATIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02122471	12-Week Study of Plecanatide for CIC (The National CIC3 Study)	Phase 3	1,410	2019-03-14	Chronic Idiopathic Constipation	PLECANATIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01696643	Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation	Phase 3	1,407	2015-09-28	Opioid-Induced Constipation	BEVENOPRAN	Its record names the disease	ClinicalTrials.gov
NCT01982240	12-Week Study of Plecanatide for CIC (The CIC3 Study)	Phase 3	1,394	2019-03-21	Chronic Idiopathic Constipation	PLECANATIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01965652	Long Term Safety of Naldemedine	Phase 3	1,246	2017-05-30	Opioid-induced Constipation	NALDEMEDINE	Its record names the disease	ClinicalTrials.gov
NCT02291679	Trial of Linaclotide in Patients With Chronic Idiopathic Constipation	Phase 3	1,223	2017-05-19	Chronic Idiopathic Constipation	LINACLOTIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01429987	The Plecanatide Chronic Idiopathic Constipation (CIC) Study	Phase 2/3	951	2017-11-29	Chronic Idiopathic Constipation	PLECANATIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00613938	A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.	Phase 3	901	2010-04-23	Arthralgia, Bunion, Hallux Valgus, Pain	OXYCODONE, TAPENTADOL	Its record names the disease	ClinicalTrials.gov
NCT01336205	Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation	Phase 3	844	2014-10-20	Opioid-Induced Constipation (OIC)	NALOXEGOL	Its record names the disease	ClinicalTrials.gov
NCT02590432	An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation	Phase 4	828	2019-08-22	Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation	LINACLOTIDE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 185

See all 185 trials

Comparisons in its trials71

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Plecanatide 3 mg vs Plecantide 6 mg: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide	14 of 224	111 of 2,146	2,370	NCT01919697	Trial comparisons
Plecanatide 3 mg vs Plecantide 6 mg: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE)	123 of 224	620 of 2,146	2,370	NCT01919697	Trial comparisons
Plecanatide 3 mg vs Plecantide 6 mg: Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From Baseline	192 of 224	1,498 of 2,146	2,370	NCT01919697	Trial comparisons
Plecanatide 3 mg vs Plecanatide 6 mg: deaths from any cause	0 of 224	1 of 2,146	2,370	NCT01919697	Trial comparisons
Plecanatide 3 mg vs Plecanatide 6 mg: serious adverse events	8 of 224	32 of 2,146	2,370	NCT01919697	Trial comparisons
CB-5945 vs Placebo: serious adverse events	40 of 703	36 of 700	1,403	NCT01696643	Trial comparisons
Naldemedine vs Placebo: serious adverse events	60 of 621	73 of 619	1,240	NCT01965652	Trial comparisons
LINZESS® 145 μg (CIC) vs LINZESS® 290 μg (IBS-C): deaths from any cause	1 of 508	0 of 318	826	NCT02590432	Trial comparisons
LINZESS® 145 μg (CIC) vs LINZESS® 290 μg (IBS-C): serious adverse events	16 of 508	6 of 318	826	NCT02590432	Trial comparisons
LINZESS® 145 μg (CIC, Open Label) vs LINZESS® 290 μg (IBS-C, Open Label): Number of Participants With Positive Treatment-Related Anti-Drug Antibodies (ADA) in Serum	3 of 498	1 of 309	807	NCT02590432	Trial comparisons

1 to 10 of 71

See all 71 comparisons in its trials

Papers from its trials99

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39988233	RESULT	1	PubMed
36925458	RESULT	1	PubMed
33273258	RESULT	1	PubMed
31384086	RESULT	1	PubMed
30130627	RESULT	1	PubMed
28986022	RESULT	1	PubMed
28906317	RESULT	2	PubMed
28371937	RESULT	1	PubMed
27313953	RESULT	1	PubMed
27144634	RESULT	1	PubMed

1 to 10 of 99

See all 99 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002203

GET https://conductscience.org/api/diseases/v1/MONDO_0002203/drugs?page=2

API reference For AI assistants